Deutsch
 
Datenschutzhinweis Impressum
  DetailsucheBrowse

Datensatz

DATENSATZ AKTIONENEXPORT
Zur Ablage hinzufügen
  Lokale TagsFreigabegeschichteDetailsÜbersicht

Freigegeben
Zeitschriftenartikel

Phototherapy of Alzheimer’s Disease: Photostimulation of Brain Lymphatics during Sleep: A Systematic Review

Urheber*innen

Semyachkina-Glushkovskaya,  Oxana
External Organizations;

Penzel,  Thomas
External Organizations;

Poluektov,  Mikhail
External Organizations;

Fedosov,  Ivan
External Organizations;

Tzoy,  Maria
External Organizations;

Terskov,  Andrey
External Organizations;

Blokhina,  Inna
External Organizations;

Sidorov,  Viktor
External Organizations;

/persons/resource/Juergen.Kurths

Kurths,  Jürgen
Potsdam Institute for Climate Impact Research;

Externe Ressourcen
Es sind keine externen Ressourcen hinterlegt
Volltexte (frei zugänglich)
Ergänzendes Material (frei zugänglich)
Es sind keine frei zugänglichen Ergänzenden Materialien verfügbar
Zitation

Semyachkina-Glushkovskaya, O., Penzel, T., Poluektov, M., Fedosov, I., Tzoy, M., Terskov, A., Blokhina, I., Sidorov, V., Kurths, J. (2023): Phototherapy of Alzheimer’s Disease: Photostimulation of Brain Lymphatics during Sleep: A Systematic Review. - International Journal of Molecular Sciences, 24, 13, 10946.
https://doi.org/10.3390/ijms241310946


Zitierlink: https://publications.pik-potsdam.de/pubman/item/item_28956
Zusammenfassung
The global number of people with Alzheimer’s disease (AD) doubles every 5 years. It has been established that unless an effective treatment for AD is found, the incidence of AD will triple by 2060. However, pharmacological therapies for AD have failed to show effectiveness and safety. Therefore, the search for alternative methods for treating AD is an urgent problem in medicine. The lymphatic drainage and removal system of the brain (LDRSB) plays an important role in resistance to the progression of AD. The development of methods for augmentation of the LDRSB functions may contribute to progress in AD therapy. Photobiomodulation (PBM) is considered to be a non-pharmacological and safe approach for AD therapy. Here, we highlight the most recent and relevant studies of PBM for AD. We focus on emerging evidence that indicates the potential benefits of PBM during sleep for modulation of natural activation of the LDRSB at nighttime, providing effective removal of metabolites, including amyloid-β, from the brain, leading to reduced progression of AD. Our review creates a new niche in the therapy of brain diseases during sleep and sheds light on the development of smart sleep technologies for neurodegenerative diseases.